These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31247194)

  • 1. Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring.
    Murphy DJ; McCoy CF; Plagianos M; RamaRao S; Merkatz R; Clark H; Boyd P; Variano B; Malcolm RK
    Contraception; 2019 Sep; 100(3):241-246. PubMed ID: 31247194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.
    Haaland RE; Holder A; Evans-Strickfaden T; Nyagol B; Makanga M; Oyaro B; Humwa F; Williams T; McLellan-Lemal E; Desai M; Huey MJ
    Contraception; 2017 Jun; 95(6):602-604. PubMed ID: 28372978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do Women Find the Progesterone Vaginal Ring Acceptable? Findings from Kenya, Nigeria, and Senegal.
    RamaRao S; Obare F; Ishaku S; Mané B; Clark H; Liambila W; Unumeri G; Birungi H; Diop N; Rajamani D; Townsend J
    Stud Fam Plann; 2018 Mar; 49(1):71-86. PubMed ID: 29393513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.
    Sivin I; Díaz S; Croxatto HB; Miranda P; Shaaban M; Sayed EH; Xiao B; Wu SC; Du M; Alvarez F; Brache V; Basnayake S; McCarthy T; Lacarra M; Mishell DR; Koetsawang S; Stern J; Jackanicz T
    Contraception; 1997 Apr; 55(4):225-32. PubMed ID: 9179454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.
    Chen JH; Wu SC; Shao WQ; Zou MH; Hu J; Cong L; Miao L; Wang C; Dong J; Gao J; Xiao BL
    Contraception; 1998 Jun; 57(6):371-9. PubMed ID: 9693396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
    PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraception with progestogens and progesterone during lactation.
    Shaaban MM
    J Steroid Biochem Mol Biol; 1991; 40(4-6):705-10. PubMed ID: 1835650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone-releasing vaginal rings for use in postpartum contraception. II. Pharmacokinetic profiles in women.
    Landgren BM; Hall PE; Cekan SZ
    Contraception; 1992 Apr; 45(4):343-9. PubMed ID: 1516366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of contraceptive vaginal rings].
    Elstein M; Jackson R; Hickling D; Assendorp R
    Contracept Fertil Sex (Paris); 1992 Jan; 20(1):15-9. PubMed ID: 12343624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
    Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
    Gallo MF; Grimes DA; Schulz KF
    Cochrane Database Syst Rev; 2003; (1):CD003552. PubMed ID: 12535478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring.
    Thompson RL; Hu J; Custodio P; Dart C; Jensen JT
    Contraception; 2022 Apr; 108():61-64. PubMed ID: 34971614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings.
    Stalter RM; Moench TR; MacQueen KM; Tolley EE; Owen DH;
    J Int AIDS Soc; 2016; 19(1):20746. PubMed ID: 27142091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from core-loaded rings.
    Matlin SA; Belenguer A; Hall PE
    Contraception; 1992 Apr; 45(4):329-41. PubMed ID: 1516365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of small doses of progesterone released from two types of vaginal rings on ovarian activity and bleeding patterns during the first postpartum year.
    Landgren BM; Jonsson B; Cekan SZ
    Contraception; 1995 Apr; 51(4):255-60. PubMed ID: 7796592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings.
    MacQueen KM; Tolley EE; Owen DH; Amico KR; Morrow KM; Moench T; Friend DR; Friedland B
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19158. PubMed ID: 25224617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.
    Liu AY; Dominguez Islas C; Gundacker H; Neradilek B; Hoesley C; van der Straten A; Hendrix CW; Beamer M; Jacobson CE; McClure T; Harrell T; Bunge K; Devlin B; Nuttall J; Spence P; Steytler J; Piper JM; Marzinke MA;
    J Int AIDS Soc; 2021 Jun; 24(6):e25747. PubMed ID: 34118115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.